NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading provider of virtual primary care services, today announced the launch of new membership plans that enable immediate access to best-in-class virtual care. LifeMD’s new plans, powered by innovative features and enhancements to its proprietary app, expand care and provide patients with the most flexibility when seeking virtual treatment.
Effective immediately, all consumers can download LifeMD’s free mobile app to gain access to its proprietary symptom checker, use its discounted prescription card and access its provider network for virtual appointments in seconds. In addition, LifeMD now offers a live appointment queue where patients can seek and receive a virtual appointment immediately, providing a best-in-class ability that addresses urgent care needs that benefit from prompt medical guidance and attention.
“As a physician, I know first-hand the importance of real-time access to a doctor, as well as the impact that the doctor-patient relationship can have on driving positive health outcomes,” said Anthony Puopolo, MD, Chief Medical Officer, LifeMD. “Our new features, including immediate queue appointments, enable patients to improve their overall health with convenient, quick access to trusted providers who can deliver exceptional care for the entire family.”
LifeMD’s new membership tiers provide flexibility for patients looking for high-quality care with or without health insurance, and are as follows:
“Whether a patient is looking for a one-time doctor visit or more comprehensive, ongoing care and coverage, our new care plans give patients choice and flexibility,” said Jessica Friedeman, Chief Marketing Officer, LifeMD. “With this launch, LifeMD is advancing a new paradigm of care – one where patients can now receive treatment from a highly rated provider within minutes and access exclusive programs such as comprehensive weight management treatment with GLP-1 medications and nutritional support.”
According to Bain and Co., by 2030 one-third of the $300B per year primary care market is expected to be disrupted by non-traditional and virtual primary providers like LifeMD. LifeMD’s highly flexible virtual primary care platform supports direct-to-consumer offerings across preventative care and wellness, urgent care, and chronic care management, as well as the needs of healthcare product companies, payers, and employers seeking cost-effective virtual care solutions that facilitate access to outcome-oriented care. The company’s release of innovative features and expansion of clinical capabilities is expected to facilitate continued membership growth and demonstrates its distinct presence in the evolving telehealth landscape.
About LifeMD
LifeMD is a leading provider of virtual primary care. The company offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions including primary care, men’s health, women’s health, allergy & asthma, and dermatology. Leveraging a vertically integrated proprietary digital care platform, 50-state affiliated medical group, and US-based patient care center, LifeMD is simplifying healthcare, increasing access to top-notch, affordable, and patient-centric care. For more information, please visit LifeMD.com.
Media Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact
Marc Benathen, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$5.04 |
Daily Change: | 0.14 2.86 |
Daily Volume: | 1,325,668 |
Market Cap: | US$218.280M |
November 07, 2024 November 06, 2024 October 23, 2024 September 19, 2024 August 07, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB